Protagen Signs Biomarker Discovery Deal with Pfizer | GenomeWeb

NEW YORK (GenomeWeb News) – Protagen said today that it has entered a collaboration agreement with Pfizer to use its SeroTag technology to identify biomarkers in support of Pfizer's drug development work.

Specifically, the collaboration aims to identify markers for stratifying patient cohorts or predicting patient response to a novel autoimmune disease drug being developed by Pfizer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.